The PML isoform IV is a negative regulator of nuclear EGFR’s transcriptional activity in lung cancer (original) (raw)

PML protein association with specific nucleolar structures differs in normal, tumor and senescent human cells

Zora Novakova

Journal of Structural Biology, 2007

View PDFchevron_right

The Effects of EGFR Exon 19 747–750 Deletion on the Risk of Developing Lung Cancer

Nazan ERAS

Medical Science and Discovery, 2019

View PDFchevron_right

Comprehensive molecular profiling of lung adenocarcinoma

Joshua Campbell

2014

View PDFchevron_right

Predictive biomarkers in the management of EGFR mutant lung cancer

Rafael Rosel

Annals of the New York Academy of Sciences, 2010

View PDFchevron_right

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

Alfredo Cesario

International Journal of Medical Sciences, 2000

View PDFchevron_right

Survival Analysis of Lung Adenocarcinoma Patients with Exon 19 Del and 21 L858R Mutations Receiving EGFR-TKI Treatment

noni soeroso

Jurnal Respirasi, 2023

View PDFchevron_right

AIF-regulated oxidative phosphorylation supports lung cancer development

Reiko Hanada

Cell Research, 2019

View PDFchevron_right

EGFR genomic alterations in cancer: prognostic and predictive values

Corrado Ficorella

Frontiers in Bioscience, 2009

View PDFchevron_right

Differentially expressed and activated proteins associated with non small cell lung cancer tissues

aurora daniele

Respiratory Research, 2015

View PDFchevron_right

Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases

Adriana Zuñiga Rojas

Frontiers in Genetics, 2019

View PDFchevron_right

EGFR and KRAS mutation coexistence in lung adenocarcinomas

Vitor Sousa

Diagnostic Pathology, 2015

View PDFchevron_right

Genomic landscape of lung cancer in the young

luis raez

Frontiers in Oncology, 2022

View PDFchevron_right

Epidermal Growth Factor 62229-50-9

Filiz Kazak

Sax's Dangerous Properties of Industrial Materials, 2004

View PDFchevron_right

Cytoplasmic EGFR Staining and Gene Amplification in Glottic Cancer

Milodar Kujundzić

Applied Immunohistochemistry & Molecular Morphology, 2014

View PDFchevron_right

The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis

Johan Kros

WFNOS 2022 Abstract Book, 2022

View PDFchevron_right

Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways

Vitor Sousa

Revista Portuguesa de Pneumologia, 2014

View PDFchevron_right

Lung cancer and Toll-like receptors

Silvana Morello

Cancer Immunology, Immunotherapy, 2011

View PDFchevron_right

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis

Johan Kros

Neuro-oncology, 2021

View PDFchevron_right

Targeted therapies in non-small cell lung cancer

Smita Rastogi Verma

Cancer Imaging, 2008

View PDFchevron_right

Anti-tissue factor short hairpin RNA inhibits breast cancer growth in vivo

Mohammed Aimad AMARZGUIOUI

Breast Cancer Research and Treatment, 2010

View PDFchevron_right

PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity

Andrea Lunardi

Oncotarget, 2016

View PDFchevron_right

Identification of Piwil2-Like (PL2L) Proteins that Promote Tumorigenesis

Andrew Issekutz

PLoS ONE, 2010

View PDFchevron_right

Targeting mTOR Signaling for Lung Cancer Therapy

Shi-Yong Sun

Journal of Thoracic Oncology, 2006

View PDFchevron_right

Evaluation of Prognostic Factors for Survival in Stage I Non-small Cell Lung Carcinoma

Omer Onal

Erciyes medical journal, 2017

View PDFchevron_right

Gene expression in inherited breast cancer

Ingrid Hedenfalk

Advances in Cancer Research, 2002

View PDFchevron_right